Tag: drug-eluting stents

paclitaxel

Without additional long-term and patient-level data, Katsanos et al’s conclusion is...

By Thomas Zeller The Katsanos et al meta-analysis reports an increased risk of mortality beyond one year across randomised studies of paclitaxel-coated balloons (DCB) and...

Third-generation drug-eluting stents and beyond: Where were we, where are we,...

Second-generation drug-eluting stents resolved the issues of late and very late stent thrombosis that were seen with the first-generation devices and have good safety...

NORSTENT shows bare metal stents have improved

The NORSTENT (Norwegian coronary stent trial) study, which was presented at the 2016 European Society of Cardiology congress (27–31 August, Rome, Italy) found no...

ESC 2016: Bare metal stents inferior to drug-eluting stents for saphenous...

Data from a new study, BASKET-SAVAGE, indicate that patients who receive a drug-eluting stent when undergoing percutaneous coronary intervention (PCI) in a saphenous venous...

ESC 2016: Drug-eluting stents are still preferred despite no long-term survival...

The results of NORSTENT (Norwegian coronary stent trial) indicate that second-generation drug-eluting stents do not significantly reduce the long-term risk of all-cause mortality compared...